| [1] | American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care 47 : S158-S178. DOI: 10.2337/dc24-S009. |
| [2] | Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova, B., Emberson, J., et al. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 380: 581−590. DOI: 10.1016/S0140-6736(12)60367-5. |
| [3] | Blood Pressure Lowering Treatment Trialists’ Collaboration, Ying, A., Arima, H., et al. (2015). Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials. Lancet 385: 867−874. DOI: 10.1016/S0140-6736(14)61171-5. |
| [4] | Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., et al. (2011). Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 343: d4169. DOI: 10.1136/bmj.d4169. |
| [5] | Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J.G., Zuñiga-Hernandez, J.A., et al. (2019). Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ 367: l5887. DOI: 10.1136/bmj.l5887. |
| [6] | Lamanna, C., Monami, M., Marchionni, N., et al. (2011). Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 13: 221−228. DOI: 10.1111/j.1463-1326.2010.01349.x. |
| [7] | Zhu, Y.-Y., Yang, Z.-Y., Li, P., et al. (2020). Comparing the incidence of major cardiovascular events and severe microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. World Journal of Meta-Analysis 8: 400−410. DOI: 10.13105/wjma.v8.i5.400. |
| [8] | UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854−865. DOI: 10.1016/S0140-6736(98)07037-8. |
| Zhang Y., Threapleton D., Shi H., et al., (2024). Effect of anti-diabetic drugs in primary prevention of cardiovascular disease in type 2 diabetes and prediabetes: A systematic review and meta-analysis of randomized trials. The Innovation Medicine 2(4): 100096. https://doi.org/10.59717/j.xinn-med.2024.100096 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Effectiveness of anti-diabetic drugs in preventing major cardiovascular events and secondary outcomes